Boone Capital Management LLC Takes Position in Astrazeneca Plc $AZN

Boone Capital Management LLC acquired a new stake in Astrazeneca Plc (NYSE:AZN) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 220,201 shares of the company’s stock, valued at approximately $39,000. Astrazeneca makes up approximately 0.0% of Boone Capital Management LLC’s holdings, making the stock its 15th biggest position.

A number of other hedge funds also recently made changes to their positions in the business. American Trust acquired a new position in shares of Astrazeneca in the 4th quarter valued at $404,000. Guggenheim Capital LLC raised its stake in shares of Astrazeneca by 2.4% in the 4th quarter. Guggenheim Capital LLC now owns 195,602 shares of the company’s stock valued at $34,328,000 after buying an additional 4,538 shares in the last quarter. ADAR1 Capital Management LLC acquired a new position in shares of Astrazeneca in the 4th quarter valued at $1,580,000. Bank OZK acquired a new position in shares of Astrazeneca in the 4th quarter valued at $4,270,000. Finally, DV Equities LLC acquired a new position in shares of Astrazeneca in the 4th quarter valued at $889,000. Institutional investors and hedge funds own 20.35% of the company’s stock.

Astrazeneca Trading Down 0.3%

AZN opened at $178.09 on Thursday. The company has a current ratio of 0.91, a quick ratio of 0.71 and a debt-to-equity ratio of 0.52. The stock has a market capitalization of $276.20 billion, a PE ratio of 26.74, a PEG ratio of 1.55 and a beta of 0.25. Astrazeneca Plc has a 1-year low of $137.23 and a 1-year high of $212.71. The firm has a 50-day moving average price of $187.81 and a two-hundred day moving average price of $186.21.

Astrazeneca (NYSE:AZN) last posted its quarterly earnings data on Wednesday, April 29th. The company reported $2.58 earnings per share for the quarter, beating the consensus estimate of $2.52 by $0.06. The firm had revenue of $15.29 billion during the quarter, compared to analysts’ expectations of $14.93 billion. Astrazeneca had a net margin of 17.19% and a return on equity of 30.86%. As a group, equities analysts anticipate that Astrazeneca Plc will post 9.39 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages recently issued reports on AZN. TD Cowen reiterated a “buy” rating on shares of Astrazeneca in a research report on Wednesday, March 18th. Wall Street Zen upgraded shares of Astrazeneca from a “hold” rating to a “buy” rating in a research report on Saturday, May 2nd. Deutsche Bank Aktiengesellschaft reiterated a “sell” rating on shares of Astrazeneca in a research report on Tuesday, June 9th. Morgan Stanley reiterated an “overweight” rating on shares of Astrazeneca in a research report on Wednesday, April 8th. Finally, Sanford C. Bernstein reiterated a “buy” rating on shares of Astrazeneca in a research report on Monday, May 4th. Twelve equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $205.33.

Astrazeneca Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.